Cingulate

Cingulate EBIT CAGR 5Y

The EBIT CAGR (5 Year) of Cingulate (CING) as of Nov 11, 2026 is 24.38 %. In the previous year, EBIT CAGR (5 Year) was 24.38 % — a change of 0.00% (lower).

EBIT CAGR 5Y

24.38 %

YoY

0.00%

Last updated:

EBIT CAGR (5 Year) of Cingulate is 2025 24.38 % . EBIT CAGR (5 Year) of Cingulate was 2024 24.38 % . It decreases by 0.00% lower compared to the previous year.

The Cingulate EBIT CAGR 5Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 5Y
Date
EBIT CAGR 5Y
Jan 1, 2019
24.38 USD
Jan 1, 2020
24.38 USD
Jan 1, 2021
24.38 USD
Jan 1, 2022
24.38 USD
Jan 1, 2023
24.38 USD
Jan 1, 2024
24.38 USD
Jan 1, 2025
24.38 USD
The Cingulate EBIT CAGR 5Y history
YEAREBIT CAGR 5YYoY
24.38 %0.00%
24.38 %0.00%
24.38 %0.00%
24.38 %0.00%
24.38 %0.00%
24.38 %0.00%
24.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

EBIT CAGR (5 Year) of Cingulate is 24.38 % in 2025.

On Eulerpool you can find the complete historical development of EBIT CAGR (5 Year) Cingulate since 2006 – with annual values, charts, and detailed analysis.

The 5-year EBIT CAGR shows the compound annual growth rate of EBIT over the past five years.

To evaluate EBIT CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (5 Year).

EBIT CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (5 Year)'s Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Cingulate

All Key Metrics — Cingulate